Cozart granted U.S. patent for technology used in its drug-detection devices

By Lisa Kerner

Charlotte, N.C., July 7 - Cozart plc said its lead products for the detection of drugs in saliva samples have been granted U.S. Patent No. 7,070,920.

The patent protects the technology used by the Cozart RapiScan, launched in Australia and Europe in 1999, and the recently launched Cozart DDS until 2025.

"Both the Cozart RapiScan and DDS have proved to be highly efficient products in the detection of drugs of abuse both in the United Kingdom and internationally," managing director Chris Hand said in a company news release.

"With the intellectual property secured in the United States, and Food and Drug Administration approval in place for Cozart RapiScan, we look forward to advancing our strategy in this important market."

Cozart is a medical diagnostics company based in Oxfordshire, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.